Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Nature Medicine, Journal Year: 2019, Volume and Issue: 25(3), P. 477 - 486

Published: Feb. 11, 2019

Language: Английский

---

Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

Neuro-Oncology, Journal Year: 2020, Volume and Issue: 22(8), P. 1073 - 1113

Published: April 20, 2020

Abstract Glioblastomas are the most common form of malignant primary brain tumor and an important cause morbidity mortality. In recent years there have been advances in understanding molecular pathogenesis biology these tumors, but this has not translated into significantly improved outcomes for patients. consensus review from Society Neuro-Oncology (SNO) European Association (EANO), current management isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. addition, novel therapies such as targeted therapies, agents targeting DNA damage response metabolism, immunotherapies, viral reviewed, well challenges future directions research.

Language: Английский

---

Neoadjuvant checkpoint blockade for cancer immunotherapy

Science, Journal Year: 2020, Volume and Issue: 367(6477)

Published: Jan. 31, 2020

Presurgical immune checkpoint blockade Checkpoint immunotherapy using antibodies that inhibit the programmed cell death 1 (PD-1) or cytotoxic T lymphocyte–associated protein 4 (CTLA-4) pathways has resulted in unprecedented clinical outcomes for certain cancers such as melanoma. Topalian et al. review advances neoadjuvant (presurgical) an important next step enhancing response of early-stage tumors to blockade. They highlight mechanistic rationale and recent trials based on anti–PD-1 ligand (anti–PD-L1) therapy. Pathological assessment criteria may provide early on-treatment biomarkers predict patient are also discussed. Science , this issue p. eaax0182

Language: Английский

---

Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells

Cell, Journal Year: 2020, Volume and Issue: 181(7), P. 1643 - 1660.e17

Published: May 28, 2020

Language: Английский

---

Mechanisms of immunotherapy resistance: lessons from glioblastoma

Nature Immunology, Journal Year: 2019, Volume and Issue: 20(9), P. 1100 - 1109

Published: July 29, 2019

Language: Английский

---

Immunotherapy for glioma: Current management and future application

Cancer Letters, Journal Year: 2020, Volume and Issue: 476, P. 1 - 12

Published: Feb. 7, 2020

Gliomas are intrinsic brain tumors that originate from neuroglial progenitor cells. Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved limited improvements in the prognosis of glioma patients. Immunotherapy, a revolution cancer treatment, has become promising strategy with ability to penetrate blood-brain barrier since pioneering discovery lymphatics central nervous system. Here we detail current management gliomas previous studies assessing different immunotherapies gliomas, despite fact associated clinical trials not been completed yet. Moreover, several drugs undergone listed as novel strategies for future application; however, these indicated efficacy glioma. Therefore, additional warranted evaluate therapeutic approaches treatment.

Language: Английский

---

Brain immunology and immunotherapy in brain tumours

Nature reviews. Cancer, Journal Year: 2019, Volume and Issue: 20(1), P. 12 - 25

Published: Dec. 5, 2019

Language: Английский

---

Glioblastoma and Other Primary Brain Malignancies in Adults

JAMA, Journal Year: 2023, Volume and Issue: 329(7), P. 574 - 574

Published: Feb. 21, 2023

Importance Malignant primary brain tumors cause more than 15 000 deaths per year in the United States. The annual incidence of malignant is approximately 7 100 individuals and increases with age. Five-year survival 36%. Observations Approximately 49% are glioblastomas, 30% diffusely infiltrating lower-grade gliomas. Other include central nervous system (CNS) lymphoma (7%) forms ependymomas (3%) meningiomas (2%). Symptoms headache (50%), seizures (20%-50%), neurocognitive impairment (30%-40%), focal neurologic deficits (10%-40%). Magnetic resonance imaging before after a gadolinium-based contrast agent preferred modality for evaluating tumors. Diagnosis requires tumor biopsy consideration histopathological molecular characteristics. Treatment varies by type often includes combination surgery, chemotherapy, radiation. For patients glioblastoma, temozolomide radiotherapy improved when compared alone (2-year survival, 27.2% vs 10.9%; 5-year 9.8% 1.9%; hazard ratio [HR], 0.6 [95% CI, 0.5-0.7]; P < .001). In anaplastic oligodendroglial 1p/19q codeletion, probable 20-year overall following without procarbazine, lomustine, vincristine was 13.6% 37.1% (80 patients; HR, 0.60 0.35-1.03]; = .06) EORTC 26951 trial 14.9% 37% RTOG 9402 (125 0.61 0.40-0.94]; .02). CNS high-dose methotrexate-containing regimens, followed consolidation therapy myeloablative chemotherapy autologous stem cell rescue, nonmyeloablative or whole Conclusions Relevance individuals, glioblastomas. Most die from progressive disease. First-line glioblastoma surgery radiation alkylating chemotherapeutic temozolomide.

Language: Английский

---

Glioma targeted therapy: insight into future of molecular approaches

Molecular Cancer, Journal Year: 2022, Volume and Issue: 21(1)

Published: Feb. 8, 2022

Gliomas are the common type of brain tumors originating from glial cells. Epidemiologically, gliomas occur among all ages, more often seen in adults, which males susceptible than females. According to fifth edition WHO Classification Tumors Central Nervous System (WHO CNS5), standard care and prognosis can be dramatically different. Generally, circumscribed usually benign recommended early complete resection, with chemotherapy if necessary. Diffuse other high-grade according their molecule subtype slightly intractable, necessity chemotherapy. However, for glioblastoma, feasible resection followed by radiotherapy plus temozolomide define current care. Here, we discuss novel or potential targets treatment gliomas, especially IDH-wild glioblastoma. Classic such as p53 retinoblastoma (RB) pathway epidermal growth factor receptor (EGFR) gene alteration have met failure due complex regulatory network. There is ever-increasing interest immunotherapy (immune checkpoint molecule, tumor associated macrophage, dendritic cell vaccine, CAR-T), microenvironment, combination several efficacious methods. With many targeted therapy options emerging, biomarkers guiding prescription a particular also attractive. More pre-clinical clinical trials urgently needed explore evaluate feasibility corresponding effective personalized options.

Language: Английский

---

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial

The Lancet Oncology, Journal Year: 2020, Volume and Issue: 21(5), P. 655 - 663

Published: April 4, 2020

Language: Английский

---